In patients with type 2 diabetes (T2D), the use of SGLT2 inhibitors significantly increased the risk of falls, and the risk was even higher when combined with GLP-1 receptor agonists. Although GLP-1 RAs alone were not significantly linked to increased falls, combined therapy raised the risk substantially.